TABLE 1.
Parameters for the cost-effectiveness model.
| Variable | Baseline value | Minimum | Maximum | Reference | Distribution |
|---|---|---|---|---|---|
| Log-logistic OS survival model with TACE | Theta = 0.00272126, Kappa = 2.184792 | — | — | Li et al. (2022) | — |
| Lognormal PFS survival model with TACE | Mu = 1.682471, Sigma = 1.119812 | — | — | Li et al. (2022) | — |
| HR of FOLFOX-HAIC group versus TACE group for OS | 0.58 | 0.45 | 0.75 | Li et al. (2022) | Lognormal |
| HR of FOLFOX-HAIC group versus TACE group for PFS | 0.57 | 0.45 | 0.72 | Li et al. (2022) | Lognormal |
| Proportion of receiving hepatectomy after FOLFOX-HAIC | 0.24 | 0.19 | 0.29 | Li et al. (2022) | Beta |
| Proportion of receiving hepatectomy after TACE | 0.12 | 0.10 | 0.14 | Li et al. (2022) | Beta |
| Proportion of recurrence of HCC | 0.19 | 0.15 | 0.20 | Zheng et al. (2017) | Beta |
| Proportion of receiving subsequent treatment on BSC after FOLFOX-HAIC | 0.95 | 0.76 | 1.14 | Li et al. (2022) | Beta |
| Proportion of receiving subsequent treatment on BSC after TACE | 0.87 | 0.70 | 1.04 | Li et al. (2022) | Beta |
| Proportion of receiving subsequent treatment on TACE after FOLFOX-HAIC | 0.05 | 0.04 | 0.06 | Li et al. (2022) | Beta |
| Proportion of receiving subsequent treatment on HAIC after TACE | 0.13 | 0.10 | 0.16 | Li et al. (2022) | Beta |
| FOLFOX-HAIC arm: Incidence of Grade ≥3 AEs | |||||
| Elevated ALT | 0.08 | 0.06 | 0.10 | Li et al. (2022) | Beta |
| Elevated AST | 0.18 | 0.14 | 0.22 | Li et al. (2022) | Beta |
| Vomiting | 0.06 | 0.05 | 0.07 | Li et al. (2022) | Beta |
| TACE arm: Incidence of Grade ≥3 AEs | |||||
| Elevated ALT | 0.19 | 0.15 | 0.23 | Li et al. (2022) | Beta |
| Elevated AST | 0.29 | 0.23 | 0.35 | Li et al. (2022) | Beta |
| Vomiting | 0.05 | 0.04 | 0.06 | Li et al. (2022) | Beta |
| Utility | |||||
| PFD | 0.76 | 0.61 | 0.91 | Li et al. (2021) | Beta |
| PD | 0.68 | 0.54 | 0.82 | Li et al. (2021) | Beta |
| AE disutility | |||||
| Elevated ALT/AST | 0 | 0 | 0 | Li et al. (2021) | Beta |
| Vomiting | 0.05 | 0.04 | 0.06 | Li et al. (2021) | Beta |
| AE cost, $/event | |||||
| Elevated ALT/AST | 43 | 35 | 52 | Li et al. (2021) | Gamma |
| Vomiting | 49 | 39 | 59 | Li et al. (2021) | Gamma |
| Discount rate | 0.03 | 0.01 | 0.05 | Sanders et al. (2016) | Uniform |
| Drug cost, US $/cycle | |||||
| Oxaliplatin | 426 | 340 | 511 | Li et al. (2021) | Gamma |
| Fluorouracil | 524 | 419 | 629 | Li et al. (2021) | Gamma |
| Leucovorin | 24 | 19 | 29 | Li et al. (2021) | Gamma |
| HAIC | 1,850 | 1,480 | 2,220 | Li et al. (2021) | Gamma |
| TACE | 1,929 | 1,543 | 2,315 | Chen et al. (2018) | Gamma |
| Hepatectomy | 9,022 | 7,218 | 10,827 | Li et al. (2021) | Gamma |
| Hospitalization | 384 | 307 | 460 | Li et al. (2021) | Gamma |
| BSC | 363 | 291 | 436 | Li et al. (2021) | Gamma |
OS, overall survival; PFS, progression-free survival; HR, hazard ratio; TACE, transarterial chemoembolization; FOLFOX-HAIC, hepatic arterial infusion chemotherapy with infusional fluorouracil, leucovorin, and oxaliplatin; AEs, adverse events; PFD, progression-free disease; PD, progressed disease; BSC, best supportive car.